213 related articles for article (PubMed ID: 35203369)
1. Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis.
Murakami K; Sasaki Y; Asahiyama M; Yano W; Takizawa T; Kamiya W; Matsumura Y; Anai M; Osawa T; Fruchart JC; Fruchart-Najib J; Aburatani H; Sakai J; Kodama T; Tanaka T
Cells; 2022 Feb; 11(4):. PubMed ID: 35203369
[TBL] [Abstract][Full Text] [Related]
2. Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content.
Sasaki Y; Asahiyama M; Tanaka T; Yamamoto S; Murakami K; Kamiya W; Matsumura Y; Osawa T; Anai M; Fruchart JC; Aburatani H; Sakai J; Kodama T
Sci Rep; 2020 May; 10(1):7818. PubMed ID: 32385406
[TBL] [Abstract][Full Text] [Related]
3. Effects of a novel selective PPARα modulator, statin, sodium-glucose cotransporter 2 inhibitor, and combinatorial therapy on the liver and vasculature of medaka nonalcoholic steatohepatitis model.
Kimura A; Kamimura K; Ohkoshi-Yamada M; Shinagawa-Kobayashi Y; Goto R; Owaki T; Oda C; Shibata O; Morita S; Sakai N; Abe H; Yokoo T; Sakamaki A; Kamimura H; Terai S
Biochem Biophys Res Commun; 2022 Mar; 596():76-82. PubMed ID: 35121372
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH).
Goto R; Kamimura K; Shinagawa-Kobayashi Y; Sakai N; Nagoya T; Niwa Y; Ko M; Ogawa K; Inoue R; Yokoo T; Sakamaki A; Kamimura H; Abe S; Nishina H; Terai S
FEBS Open Bio; 2019 Apr; 9(4):643-652. PubMed ID: 30984539
[TBL] [Abstract][Full Text] [Related]
5. The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis-associated liver tumors in a novel murine model.
Yoshioka N; Tanaka M; Ochi K; Watanabe A; Ono K; Sawada M; Ogi T; Itoh M; Ito A; Shiraki Y; Enomoto A; Ishigami M; Fujishiro M; Ogawa Y; Suganami T
Biomed Pharmacother; 2021 Aug; 140():111738. PubMed ID: 34029949
[TBL] [Abstract][Full Text] [Related]
6. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis.
Honda Y; Kessoku T; Ogawa Y; Tomeno W; Imajo K; Fujita K; Yoneda M; Takizawa T; Saito S; Nagashima Y; Nakajima A
Sci Rep; 2017 Feb; 7():42477. PubMed ID: 28195199
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis.
Chun HJ; Kim ER; Lee M; Choi DH; Kim SH; Shin E; Kim JH; Cho JW; Han DH; Cha BS; Lee YH
Metabolism; 2023 Aug; 145():155612. PubMed ID: 37277060
[TBL] [Abstract][Full Text] [Related]
8. The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice.
Araki M; Nakagawa Y; Oishi A; Han SI; Wang Y; Kumagai K; Ohno H; Mizunoe Y; Iwasaki H; Sekiya M; Matsuzaka T; Shimano H
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30041488
[TBL] [Abstract][Full Text] [Related]
9. The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma.
Jojima T; Wakamatsu S; Kase M; Iijima T; Maejima Y; Shimomura K; Kogai T; Tomaru T; Usui I; Aso Y
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31652578
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice.
Tahara A; Takasu T
Endocr Res; 2020; 45(2):147-161. PubMed ID: 31955626
[No Abstract] [Full Text] [Related]
11. Effects of a selective PPARα modulator, sodium-glucose cotransporter 2 inhibitor, and statin on the myocardial morphology of medaka nonalcoholic fatty liver disease model.
Ohkoshi-Yamada M; Kamimura K; Kimura A; Tanaka Y; Nagayama I; Yakubo S; Abe H; Yokoo T; Sakamaki A; Kamimura H; Terai S
Biochem Biophys Res Commun; 2022 Oct; 625():116-121. PubMed ID: 35952608
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of IL-33 signaling ameliorate hepatic fibrosis with decreasing MCP-1 in a mouse model of diabetes and non-alcoholic steatohepatitis; comparison for luseogliflozin, an SGLT2 inhibitor.
Wakamatsu S; Jojima T; Hashiguchi M; Kishi H; Niitani T; Sakurai S; Iijima T; Kogai T; Tomaru T; Usui I; Aso Y
J Diabetes Complications; 2024 Jan; 38(1):108650. PubMed ID: 38035640
[TBL] [Abstract][Full Text] [Related]
13. Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glucose Metabolism, Liver Function, Ascites, and Hemodynamics in a Mouse Model of Nonalcoholic Steatohepatitis and Type 2 Diabetes.
Yabiku K; Nakamoto K; Tsubakimoto M
J Diabetes Res; 2020; 2020():1682904. PubMed ID: 33457424
[TBL] [Abstract][Full Text] [Related]
14. Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease.
Nakajima A; Eguchi Y; Yoneda M; Imajo K; Tamaki N; Suganami H; Nojima T; Tanigawa R; Iizuka M; Iida Y; Loomba R
Aliment Pharmacol Ther; 2021 Nov; 54(10):1263-1277. PubMed ID: 34528723
[TBL] [Abstract][Full Text] [Related]
15. Association of increased hepatic insulin clearance and change in serum triglycerides or β-hydroxybutyrate concentration via the sodium/glucose-cotransporter 2 inhibitor tofogliflozin.
Matsubayashi Y; Yoshida A; Suganami H; Osawa T; Furukawa K; Suzuki H; Fujihara K; Tanaka S; Kaku K; Sone H
Diabetes Obes Metab; 2020 Jun; 22(6):947-956. PubMed ID: 31984623
[TBL] [Abstract][Full Text] [Related]
16. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH.
Shiba K; Tsuchiya K; Komiya C; Miyachi Y; Mori K; Shimazu N; Yamaguchi S; Ogasawara N; Katoh M; Itoh M; Suganami T; Ogawa Y
Sci Rep; 2018 Feb; 8(1):2362. PubMed ID: 29402900
[TBL] [Abstract][Full Text] [Related]
17. The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis.
Hennuyer N; Duplan I; Paquet C; Vanhoutte J; Woitrain E; Touche V; Colin S; Vallez E; Lestavel S; Lefebvre P; Staels B
Atherosclerosis; 2016 Jun; 249():200-8. PubMed ID: 27108950
[TBL] [Abstract][Full Text] [Related]
18. Gene Expression Profiles Induced by a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα) Pemafibrate.
Sasaki Y; Raza-Iqbal S; Tanaka T; Murakami K; Anai M; Osawa T; Matsumura Y; Sakai J; Kodama T
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31766193
[TBL] [Abstract][Full Text] [Related]
19. Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model.
Morishita A; Tadokoro T; Fujihara S; Iwama H; Oura K; Fujita K; Tani J; Takuma K; Nakahara M; Shi T; Haba R; Okano K; Nishiyama A; Ono M; Himoto T; Masaki T
PLoS One; 2022; 17(2):e0261310. PubMed ID: 35192632
[TBL] [Abstract][Full Text] [Related]
20. Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?
Fruchart JC; Hermans MP; Fruchart-Najib J; Kodama T
Curr Atheroscler Rep; 2021 Jan; 23(1):3. PubMed ID: 33392801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]